

(Pub. L. 117–103), division H, title II, which requires that “institutions that receive funds through a grant or cooperative agreement during fiscal year 2022 and in future years to notify the Director when individuals identified as a principal investigator or as key personnel in an NIH notice of award are removed from their position or are otherwise disciplined due to concerns about harassment, bullying, retaliation, or hostile working conditions.” The Harassment Web Form will be used as a secure and confidential portal by

which recipient institutions notify NIH when individuals identified as PD/PI or other Senior/Key personnel in an NIH notice of award are removed from their position or are otherwise disciplined by the recipient institution due to concerns about harassment, bullying, retaliation or hostile working conditions, as specified in NOT–OD–22–129. Notification must be provided by the Authorized Organization Representative within 30 days of the removal or disciplinary action and must be submitted to NIH through the

Harassment Web Form. All required notifications must include, at a minimum, the name of the Authorized Organization Representative submitting the notification, the name of the individual of concern, a description of the concerns, the action(s) taken, and any anticipated impact on the NIH-funded award(s).

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 60.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Private Sector	240	1	15/60	60
Total	240	60

Dated: September 15, 2022.
Tara A. Schwetz,
Acting Principal Deputy Director, National Institutes of Health.
 [FR Doc. 2022–20468 Filed 9–20–22; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Developmental Biology Study Section.
Date: October 14, 2022.
Closed: 10 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B

Rockledge Drive, 2131B, Bethesda, MD 20892–7510 (Video Assisted Meeting).
Contact Person: Jolanta Maria Topczewska, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Rm. 2131B, Bethesda, MD 20892, (301) 451–0000, jolanta.topczewska@nih.gov.

Name of Committee: Health, Behavior, and Context Study Section.

Date: October 17, 2022.
Closed: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, 2137C, Bethesda, MD 20892–7510 (Video Assisted Meeting).

Contact Person: Kimberly L. Houston, MD, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2137C, Bethesda, MD 20892, (301) 827–4902, kimberly.houston@nih.gov.

Name of Committee: Obstetrics and Maternal-Fetal Biology Study Section.

Date: October 28, 2022.
Closed: 10 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, 2127D, Bethesda, MD 20892–7510 (Video Assisted Meeting).

Contact Person: Luis E. Dettin, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2127D, Bethesda, MD 20892, (301) 827–8231, luis.dettin@nih.gov.

Information is also available on the Institute’s/Center’s home page: <https://>

www.nichd.nih.gov/about/org/der/srb where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS.)

Dated: September 15, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–20400 Filed 9–20–22; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-Day Comment Request; NIH Information Collection Forms To Support Genomic Data Sharing for Research Purposes (OD)

AGENCY: National Institutes of Health, HHS.
ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institutes of Health Office of the Director (OD) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

DATES: Comments regarding this information collection are best assured of having their full effect if received

within 60 days of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Julia Slutsman, Ph.D., Director, Genomic Data Sharing Policy Implementation Team, Office of Extramural Research, NIH, Office of Extramural Research, OD, NIH 6705 Rockledge Dr. (RKL1), Room 800–C, Bethesda, MD 20892, or call non-toll-free number (301)-594-7783 or email your request including your address to: sharing@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information from those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Proposed Collection Title: NIH Information Collection Forms to Support Genomic Data Sharing for Research Purposes—0925–0670—Expiration Date 11/31/2022—

REVISION—Office of the Director (OD), National Institutes of Health (NIH).

Need and Use of Information Collection: Sharing research data supports the National Institutes of Health (NIH) mission and is essential to facilitate the translation of research results into knowledge, products, and procedures that improve human health. NIH has longstanding policies to make a broad range of research data, including genomic data, publicly available in a timely manner from the research activities that it funds. Genomic research data sharing is an integral element of the NIH mission as it facilitates advances in our understanding of factors that influence health and disease, while also providing opportunities to accelerate research through the power of combining large and information-rich datasets. To promote robust sharing of human and non-human data from a wide range of large-scale genomic research and provide appropriate protections for research involving human data, the NIH issued the NIH Genomic Data Sharing Policy (NIH GDS Policy). Human genomic data submissions and controlled-access genomic and related phenotypic data are managed through the database of Genotypes and Phenotypes (dbGaP) which is administered by the National Center for Biotechnology Information (NCBI), part of the National Library of Medicine at NIH.

Under the NIH GDS Policy, all investigators who receive NIH funding to conduct large-scale genomic research are expected to register studies with human genomic data in Database of Genotypes and Phenotypes (dbGaP), no matter which NIH-designated data repository will ultimately maintain the data. As part of the study registration process, investigators must provide basic study information such as the type of data that will be submitted to dbGaP,

a description of the study, and an institutional assurance (*i.e.*, provided through submission of an Institutional Certification form) of the data submission which delineates any necessary limitations on the secondary use of the data (*e.g.*, data cannot be shared with for-profit companies, data can be used only for research of particular diseases).

Investigators interested in using controlled-access data for secondary research must apply through dbGaP and be granted permission from the relevant NIH Data Access Committee(s). As part of the application process, investigators and their institutions must provide information such as a description of the proposed research use of controlled-access datasets that conforms to any data use limitations, agree to the Genomic Data User Code of Conduct, and agree to the terms of access through a Data Use Certification agreement. Requests to renew data access and reports to close out data use are similar to the initial data access request, requiring sign-off by both the requestor and the institution, but also ask for information about how the data have been used, and about publications, presentations, or intellectual property based on the research conducted with the accessed data as well as any data security issues or other data management incidents.

NIH has developed online forms, available through the Database of Genotypes and Phenotypes (dbGaP), in an effort to minimize burden for researchers and their institutional officials completing the study registration, data submission, data access, and renewal and closeout processes.

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 72,301 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Study Registration and Data Submission					
dbGaP Registration and Submission	Investigator Submitting Data	1,050	1	45/60	788
Institutional Certification	Investigator filling out Institutional Certification.	1,050	1	45/60	788
Institutional Certification	Institutional Official to Certify Institutional Certification.	1,050	1	30/60	525
Requesting Access to Data					
Data Access Request	Requester Submitting Request	3,900	10	45/60	29,250

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Data Access Request	Institutional Signing Official to Certify Request.	3,900	10	30/60	19,500
Project Renewal or Project Close-out					
Project Renewal or Project Close-out form.	Requester Submitting Request	3,900	10	15/60	9,750
Project Renewal or Project Close-out form.	Institutional Signing Official to Certify Request.	3,900	10	18/60	11,700
Total	18,750	159,150	72,301

Dated: September 15, 2022.

Tara A. Schwetz,

Acting Principal Deputy Director, National Institutes of Health.

[FR Doc. 2022–20467 Filed 9–20–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2022 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting an administrative supplement (in scope of the parent award) up to \$20,833 (total costs) for one-year to the Improving Access to Overdose Treatment grant recipients for a total of up to \$104,165 (total funding). These recipients were funded in FY 2018 with a project end date of September 30, 2023. The supplemental funding will be utilized specifically to increase the number of health care providers and pharmacists who receive training and technical assistance on the prescribing of drugs or devices approved or cleared under the FDA for emergency treatment of known or suspected opioid overdose.

FOR FURTHER INFORMATION CONTACT: Judith Ellis, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, telephone (240) 276–2567; email: judith.ellis@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION: Awardees will further collaborations with healthcare providers and pharmacists to

educate them on overdose dangers and standing orders for FDA-approved overdose reversal drugs to patients and individuals who support persons at high-risk for overdose.

The required activities for this supplement are as follows:

- Increase use of SAMHSA’s Opioid Overdose Prevention Toolkit as a guide to develop and implement a comprehensive prevention program to reduce the number of prescription drug/opioid overdose-related deaths and adverse events among cases of known or suspected opioid overdose.

- Provide technical assistance to collaborating partner organizations and practitioners in the implementation of a comprehensive prevention program to reduce the number of prescription drug/opioid overdose-related deaths and adverse events.

- Collaborate with additional pharmacies to distribute drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose, as permitted by state law.

- Provide targeted public education on the state’s “Good Samaritan” laws related to a drug overdose, if applicable, such as those that permit bystanders to alert emergency responders to an overdose or to administer drugs or devices approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose without fear of civil or criminal penalties.

This is not a formal request for application. Assistance will only be provided to the Improving Access to Overdose Treatment Funding Opportunity SP–18–006 grant recipients based on the receipt of a satisfactory application and associated budget that is approved by a review group.

Funding Opportunity Title: FY 2018 Improving Access to Overdose

Treatment Funding Opportunity SP–18–006.

Assistance Listing Number: 93.243.

Authority: Section 516 of the Public Health Services Act, as amended.

Justification: Eligibility for this supplemental funding is limited the Improving Access to Overdose Treatment Funding Opportunity SP–18–006 grant recipients funded in FY 2018. These organizations are uniquely positioned to provide training and technical assistance to organizations and practitioners in prescription drug overdose prevention activities being funded through this supplement.

Carlos Graham,

Reports Clearance Officer.

[FR Doc. 2022–20436 Filed 9–20–22; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA–4665–DR; Docket ID FEMA–2022–0001]

Missouri; Major Disaster and Related Determinations

AGENCY: Federal Emergency Management Agency, Department of Homeland Security (DHS).

ACTION: Notice.

SUMMARY: This is a notice of the Presidential declaration of a major disaster for the State of Missouri (FEMA–4665–DR), dated August 8, 2022, and related determinations.

DATES: The declaration was issued August 8, 2022.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and Recovery, Federal Emergency Management Agency, 500 C Street SW, Washington, DC 20472, (202) 646–2833.